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Cost-containment measures in healthcare provision include the implementation of therapeutic and generic drug substitution strategies
in patients whose condition is already well controlled with pharmacotherapy. Treatment for hypertension is frequently targeted for
such measures. However, drug acquisition costs are only part of the cost-effectiveness equation, and a variety of other factors need to
be taken into account when assessing the impact of switching antihypertensives. From the clinical perspective, considerations include
maintenance of an appropriate medication dose during the switching process; drug equivalence in terms of clinical effectiveness; and
safety issues, including the diverse adverse-event profiles of available alternative drugs, differences in the ‘inactive’ components of drug
formulations and the quality of generic formulations. Patients’ adherence to and persistence with therapy may be negatively influenced
by switching, which will also impact on treatment effectiveness. From the economic perspective, the costs that are likely to be incurred
by switching antihypertensives include those for additional clinic visits and laboratory tests, and for hospitalization if required to
address problems arising from adverse events or poorly controlled hypertension. Indirect costs and the impact on patients’ quality of
life also require assessment. Substitution strategies for antihypertensives have not been tested in large outcome trials and there is little
available clinical or economic evidence on which to base decisions to switch drugs. Although the cost of treatment should always be
considered, careful assessment of the human and economic costs and benefits of antihypertensive drug substitution is required before
this practice is recommended.
Introduction
Hypertension is one of the strongest modifiable risk
factors for cardiovascular and kidney disease and has been
identified as the leading risk factor for mortality [1]. In
2000,hypertensionwas estimated to affect almost 1 billion
patients worldwide and its prevalence is predicted to
increase by approximately 60% by 2025 [2]. In European
countries the prevalence of hypertension in adults is esti-
mated to be approximately 44% [3]. Given the increasing
prevalence of hypertension and the continually rising
expense of its treatment,measures that influence prescrib-
ing patterns could have a considerable impact on health
expenditure.
Cost-containment measures in healthcare provision
include drug switches without medical reason in patients
whose condition is already well controlled with pharmaco-
therapy.Thismay take the formof therapeutic substitution,
which encompasses switching within a drug class (i.e. the
chemical entities are different but the main therapeutic
mechanism of action is the same) or between classes (i.e.
the active chemical entities and mechanisms of action are
different). Patients may also be switched from a branded
drug to a generic version (i.e. the active chemical entity is
the same and the generic meets the criteria for bioequiva-
lence with the original branded version). In some coun-
tries, such as the USA and Canada, switching can be
performed by the pharmacist, without consulting the pre-
scribing clinician or the patient. Such approaches are the
subject of considerable debate, and several professional
bodies (e.g. the American Medical Association [4], the
American College of Cardiology and the American Heart
Association [5]) oppose therapeutic substitution without
prior authorization by the prescribing physician.
Switching of drugs is increasingly being mandated by
the implementation of local or national healthcare cost-
containment policies. In the UK, the Department of Health
is currently consulting on the implementation of generic
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substitution in the English primary care system [6]. The
prescribing doctor will need to indicate actively that a
branded drug should not be substituted, otherwise a
generic will be dispensed where possible.This approach is
already in place in many countries including the USA and
Canada [7].A tactic widely used in the USA is to implement
‘step therapy’ programmes, based on grouping drugs into
tiers by cost [8,9].Drugs in the second tier (usually branded
drugs) are only covered by the healthcare plan if drugs in
the first tier (usually generics) have been prescribed but
found unsuitable for the patient. A second-tier drug may
be dispensed if the patient provides a co-payment or if
specifically requested by the prescribing doctor. Other
approaches that are likely to requiremedically unnecessary
drug switching include‘referencedrug’programmes,which
permit reimbursement up to the cost of a preferred drug,
and mandatory therapeutic substitution, which requires
patients to switch to the cheapest medication in a class [8,
10]. With all of these approaches it is assumed that cost
savingswill bemadewhen thesepolicies are implemented.
In practice, a careful assessment of the potential ben-
efits and costs of drug substitution should be applied.
However, the full clinical and economic implications of
drug switches are unknown and this may not be appreci-
ated or considered by those implementing the switch.
Cost-effectiveness analyses of such approaches rarely take
into account costs other than drug acquisition costs and
assume equal effectiveness without adverse effects, but
without evidence [11–13].
The aim of this review is to highlight the potential clini-
cal and economic implications associated with switching
medications solely for cost-containment purposes in
patients whose condition is already controlled with phar-
macotherapy. These issues are illustrated with examples
from the treatment of hypertension,particularly the renin–
angiotensin system antihypertensives, angiotensin recep-
tor blockers (ARBs) and angiotensin-converting enzyme
inhibitors (ACEIs). From the clinical perspective we aimed
to examine any potential means by which switching to a
generic drug, a drug in the same class or a drug in another
class might compromise the effectiveness and safety of
antihypertensive therapy. From the economic perspective,
we examined possible causes of additional healthcare
resource use and how the cost-effectiveness of therapy
could be affected by medication switching.
Methods
This qualitative review was based on literature searches
conducted using PubMed to identify English language
articles on switching antihypertensives and on switching
medications in general.Reference lists of identified articles,
including previous relevant systematic and qualitative
reviews,were also examined for additional relevant studies
and information. The review includes evaluation of
information on: resource use and costs associated with
switching, patient adherence and persistence with antihy-
pertensives, patient satisfaction with switching, efficacy
and safety aspects of ARBs and ACEIs, drug formulation
differences, and guidelines for switching antihyperten-
sives. Searches were conducted on PubMed and were gen-
erally limited to recent publications (previous 10 years).
Search terms included combinations of the following:
(angiotensin OR hypertension OR antihypertensive), (switch
OR interchange OR conversion OR substitution OR generic),
(adherence OR persistence OR compliance OR discontinua-
tion),(costOReconomicORpharmacoeconomic),(perception
OR attitudeOR satisfaction), formulation,guidelines, generic.
Switching antihypertensives: are
clinical effectiveness and safety
maintained?
Implementing switching
At present, the guidance for physicians and pharmacists on
switching antihypertensives is poor.There is little informa-
tion on equivalent doses or guidance to ensure that blood
pressure control is maintained following drug substitution,
although health authorities may provide some guidance
[14].Concerns have also been raised with regard to switch-
ing between statins. A study of patients switching from
atorvastatin to simvastatin found that a lower therapeutic
dose was prescribed in 38% of the switches made, which
could potentially have an adverse effect on patients’
health [15].
In the absence of clear guidance, and given the sub-
stantial within-patient variation in response to antihyper-
tensive drug classes [16], when a switch is made, the new
drug is likely to be initially administered at a low dose and
titrated upwards. A delay can thus occur in regaining
hypertension control, which could impact on clinical out-
comes in patients at high cardiovascular risk. Even short
periods of uncontrolled hypertension can lead to an
increased risk of major cardiovascular events. This was
demonstrated in the Valsartan Antihypertensive Long-
term Use Evaluation (VALUE) trial in which subjects with
inadequate blood pressure control for a few weeks or
months had a higher risk of stroke, myocardial infarction
and death compared with those who had adequately con-
trolled blood pressure [17].A randomized study in primary
care has reported better blood pressure control in the first
3 months of antihypertensive treatment when a stepwise
add-on approach was used compared with an approach
allowing drug switching [18], suggesting that switching
may delay achieving control. Health professionals have
expressed concern regarding switches made for nonmedi-
cal reasons in patients with hypertension [19]. Table 1 illus-
trates the potential differences and lack of evidence that
may accompany a switch from a branded ARB to possible
alternatives, this being a switch likely to be considered for
economic reasons in clinical practice in the future.
Drug substitution in hypertension
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Evidence-based medicine and switching
A factor that should be considered for both between- and
within-class switching is the level of available evidence for
the safety and effectiveness of individual drug formula-
tions. This is particularly important when considering the
patient’s comorbidities and risk factors because individual
drugs, even within the same class, can have different
licensed indications. In addition, trial data may be limited
to surrogate markers, i.e. blood pressure, rather than clini-
cal outcomes.Although drugs may have a similar effect on
surrogate markers for a medical condition, it should not be
assumed that the clinical outcomes will also be similar. For
example,analysis of subjects receivingmonotherapy in the
VALUE study revealed a significantly lower incidence of
heart failure in the valsartan-treated group than in the
amlodipine-treated group, despite similar blood pressure
reductions [20]. The Losartan Intervention For Endpoint
reduction in hypertension (LIFE) study demonstrated that
in patients with essential hypertension and left ventricular
hypertrophy, treatment with losartan prevented signifi-
cantly more cardiovascular morbidity and mortality than
atenolol, despite similar lowering of blood pressure [21].
Likewise, in the Anglo-Scandinavian Cardiac Outcomes
Trial - Blood Pressure Lowering Arm (ASCOT-BPLA), greater
differences in the incidence of cardiovascular outcomes
were observed between the groups receiving amlodipine
and atenolol than would be expected from the small
between-treatment difference that was observed in sys-
tolic blood pressure [22].
Substitution strategies have not been tested in large
outcome studies in hypertension, except those switches
dictated by the emergence of adverse effects. Such studies
have generally used stepwise add-on drug strategies.
Virtually all the hypertension outcome trials that showed
the benefits of drug-induced blood pressure reduction
in terms of cardiovascular event prevention (HOT [23],
ALLHAT [24], LIFE [21], VALUE [17], ASCOT [22], ONTARGET
[25], etc.) have used strict stepwise upward-titration drug
treatment regimens, and substitution was only allowed in
the event of adverse effects.Thus the efficacy and safety of
the practice of substitution in the absence of adverse
effects has never been thoroughly studied in large trials.
Considerations specific to the different types of drug
switching will be discussed below.
Drug formulation considerations
Even within a class, drugs vary in a multitude of aspects.
Even subtle differences in the structure of active ingredi-
ents, drug formulation, interventions to modify (prolong)
the duration of drug action, and the ‘inactive’ ingredients
can lead to differences in activity and pharmacokinetics
and, hence, side effects. For example, a study of rifampicin
powders produced by different manufacturers found that
the crystal form of the drug varied among manufacturers
and between batches from the same manufacturer [26].
These disparities caused differences in the dissolution rate
and hence could affect drug bioavailability.
Formulation and excipient differences may also
introduce unexpected adverse effects, e.g. allergic reac-
tions [27] or interactions with other drugs. Differences in
gluten or lactose content could, e.g. alter gut motility in
some patients, while substituted drugs may introduce
additives with allergenic potential [27]. Although excipi-
ents such as polysorbate 80 and polyoxyethylated castor
oil are considered inert, there are examples of altered
drug metabolism with such compounds [28, 29]. In addi-
tion, differences in their elimination could affect drug dis-
position [30]. The true impact of these factors on patients’
care in general practice with regard to the incidence of
unexpected events is unknown and difficult to quantify.
Switching between different drug classes
A common form of drug substitution in the treatment of
hypertension is to switch between ARBs and ACEIs. These
drug classes are widely regarded as being therapeutically
equivalent in terms of reducing blood pressure. For certain
drugs in defined patient populations, clinical outcomes
have also been shown to be similar. For example, the large
ONgoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial (ONTARGET) demonstrated
that telmisartan 80 mgwas equivalent to ramipril 10 mg in
reducing the incidence of cardiovascular events in patients
with vascular disease or high-risk diabetes, without heart
failure [25]. However, equivalence between any ARB and
any ACEI has not been proved. The UK’s National Institute
Table 1
Illustration of similarities and possible differences between a reference
branded ARB and potential alternatives
Aspect of branded ARB
Generic
ARB*
Any other
ARB
Any
ACEIs
Main mechanism of action ≡ ≡ 
Structure of drug ≡  
Excipients and binders   
Appearance   
Pharmacokinetics
In healthy subjects ≡ NR NR
In patients ? NR NR
In special populations ? NR NR
Evidence for similar efficacy
Primary outcome (surrogate marker) ? ? ?
Clinical cardiovascular outcomes ?  
In same clinical indications ?  
Pleiotropic effects ?  
Safety
Adverse events ?  
Drug–drug interactions ?  
Contraindications and warnings ≡  
Adherence and persistence   
*No generic ARBs are currently available; based on evidence usually available for
an approved generic version of a drug. ≡, equivalent, , not equivalent, ?,
equivalence may not be proved or evidence suggests differences may occur. ACEI,
angiotensin-converting enzyme inhibitor, ARB, angiotensin receptor blocker, NR,
not relevant.
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for Health and Clinical Excellence states that ‘they should
be treated as equal in terms of efficacy’, although the basis
for this decision is not clear [31]. The USA’s Agency of
Healthcare Research and Quality (AHRQ) concluded that
ACEIs and ARBs have similar long-term effects on blood
pressure, a surrogate marker for clinical outcomes, in
patients with essential hypertension, but also noted that
there is insufficient evidence to determine equivalence
between ACEIs and ARBs with respect to mortality, major
cardiovascular events or quality of life outcomes [32].
When switching between drugs, physicians need to
consider the individual patient’s comorbidities and the
most suitable drug.Some guidelines specify that switching
should not occur in patients with certain comorbidities.For
example, some state that patients with heart failure,diabe-
tes mellitus or diabetic nephropathy should not be
switched from an ARB [14].
Other evidence suggests that there are differences in
effectiveness between ARBs and ACEIs. Crossover studies
have demonstrated that individual patients respond differ-
ently to drugs in the two classes [33–36]. For example, a
study in patients with essential hypertension found that
although there was a significant correlation between
responses to lisinopril and telmisartan (r = 0.77, P < 0.001),
19% of patients showed a difference between the two
drugs in their systolic blood pressure response and 25%
showed a difference in their diastolic blood pressure
response [36]. Similar results were seen in a study compar-
ing responses to candesartan and lisinopril in patients with
essential hypertension: while 50% of patients responded
to both drugs and 16% to neither, 20% responded to the
ACEI but not the ARB and 15% responded to the ARB but
not the ACEI [34].
So-called ‘pleiotropic’ effects differ between the drug
classes and may confer particular advantages.There is evi-
dence that the ARBs and/or ACEIs may be associated with
antiatherogenic, antioxidant, antidiabetic, antiplatelet and
atrial antifibrillatory effects [37, 38] and valsartan, in par-
ticular,may be associated with improvements in cognitive
function [39]. In reviewing potential effects on clinical out-
comes other than hypertension, the AHRQ concluded that
there were no consistent differences between ACEIs and
ARBs with regard to lipid concentrations, progression to
type 2 diabetes mellitus, markers of carbohydrate
metabolism/diabetes control, left ventricular mass or renal
disease progression [32].
Safety issues may preclude switching between the ARB
and ACEI classes. Persistent dry cough is common with
ACEIs, occurring in up to 20% of patients, and is a frequent
cause of medication discontinuation [25, 32, 40, 41]. By
contrast, treatment with ARBs has not been associated
with cough [42]. In addition, ACEIs are associated with
angioedema. Although the incidence is thought to be low
(0.1–0.2% [25, 43–46]), higher rates have been reported
[47, 48]. The risk of experiencing angioedema is consider-
ably lower with ARBs [25, 49–54]. The European Society
of Hypertension and European Society of Cardiology
included angioneurotic oedema as a contraindication to
the use of ACEIs but not ARBs [55].
Class-specific drug–drug interactions need to be taken
into account when considering a drug switch. There are
few differences between ARBs and ACEIs with regard to
potential drug–drug interactions [56].However,absorption
of ACEIs is possibly reduced by antacids, and ACEIs may
enhance the hypoglycaemic effect of insulin, sulphonyl-
ureas and metformin. ARBs may increase the blood con-
centration of lithium. Contraindications and warnings will
vary between drugs of different classes. An important dif-
ference between ARBs and ACEIs is that, unlike ARBs,ACEIs
are predominantly excreted by glomerular filtration. Great
caution is thus required when switching patients with
renal insufficiency from ARBs to ACEIs [41, 57].
Another aspect to consider is patient compliance with
therapy. Adherence to and persistence with antihyperten-
sives are acknowledged to be poor [58, 59]. This is an
important issue when treating hypertension: several
studies have shown that poor adherence to and persis-
tence with antihypertensives lead to suboptimal blood
pressure control and hence reduced cardiovascular protec-
tion [60–65]. Thus, when considering making a switch it is
worth taking into account that patient persistence with
therapy in clinical practice has repeatedly been shown to
be better with ARBs than with ACEIs [32, 66–69].This was
clearly evident in the ONTARGET study in which patients
randomized to receive an ARB had a significantly lower
rate of discontinuation due to adverse events, such as
cough and angioedema, compared with those receiving
an ACEI, despite the fact that patients with intolerance to
ACEIs had been excluded from the study [25].
Within-class substitutions
Therapeutic substitution may also take the form of switch-
ing between drugs in the same class. As head-to-head
comparisons are not always performed, there may be a
tendency to extrapolate efficacy data from biomarkers
between drugs within the same class (i.e. to assume ‘class
effects’). However, even within a class there may be impor-
tant differences in structure, therapeutic and adverse
actions and interactions [70].An example of how switching
between drugs within a class can have a detrimental clini-
cal effect comes from an observational database study of
patients who were switched from atorvastatin to simvas-
tatin [71]. The risk of death or first major cardiovascular
event was significantly associated with switching com-
pared with matched controls who did not switch (hazard
ratio 1.30, 95% confidence interval [CI] 1.02, 1.64) [71].
Furberg & Psaty have discussed the potential problems
that may arise through extrapolating proof of efficacy
between drugs within a class [72]. Taking ACEIs as an
example, the authors noted that of the 10 marketed ACEIs
approved by the US Food and Drug Administration (FDA)
for the treatment of hypertension, five had not been
Drug substitution in hypertension
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shown to reduce mortality/morbidity for any indication.
Three of the ACEIs were approved for indications such as
left ventricular dysfunction/heart failure after myocardial
infarction on the basis of improvements in surrogate end-
points rather than outcome data. The authors also high-
lighted the fact that trials using surrogate endpoints are
not of sufficient duration to prove long-term safety.
Differences in clinical outcomes between individual
drugs do need to be considered. Although some meta-
analyses have found no difference between ARBs with
respect to blood pressure lowering [73, 74], others have
noted significant differences [75]. Drug indications may
differ based on clinical evidence. For example, valsartan is
indicated for postmyocardial infarction left ventricular
failure and left ventricular dysfunction, for which other
ARBs, such as losartan, are not indicated. Similarly, in the
ARB class only losartan and irbesartan are indicated for
patients with diabetic nephropathy.
Structural differences between drugs within a class
may lead to drug-specific beneficial or adverse effects.
There are no clear distinctions between the different ARBs
in terms of pleiotropic effects. However, there are some
interesting reports of possible differences, including
effects on insulin sensitivity, C-reactive protein, arterial
stiffness, atrial fibrillation and superoxide dismutase
expression [76–80]. At present, the clinical relevance of
these observations remains to be proved.
Drug–drug interaction profiles vary between members
of a drug class. ARBs have a low potential for drug–drug
interactions compared with other antihypertensives.
However, variations within the class have been detected,
mainly due to differing affinities for cytochrome P450
(CYP) isoenzymes. For example, losartan is converted to its
active metabolite by CYP2C9 and CYP3A4 [81,82] and thus
has the potential to interact with drugs such as fluconazole
and rifampicin [83, 84]. By contrast, other ARBs such as
valsartan are not metabolized by cytochrome P450 [85]
and therefore drug–drug interaction at the level of liver
enzyme-mediated metabolism is unlikely.
Clearly, equivalent efficacy and safety should not be
assumed even for drugs within the same class. Rather, the
physician needs to base prescribing decisions on the
clinical outcome evidence for the particular drug.
Generic substitution
The general perception among physicians is that an
approved generic version of a drug is identical to the
branded original and can be prescribed without further
consideration. However, for marketing approval, a generic
drug only needs to demonstrate equivalent average phar-
macokinetic properties to the originator drug. Neither
proof of safety nor equivalent efficacy for a clinical end-
point(s) are required by the FDA or the European Agency
for the Evaluation of Medicinal Products. For ‘equivalence’,
the mean ratio of key pharmacokinetic parameters
(maximum plasma concentration and area under the
concentration–time curve) of the generic drug must have
a 90% CI within 0.80 and 1.25 of the original – i.e. in per-
centage terms, the average deviation must be within
80–125% of the original, although narrower ranges may
apply in some instances. Required bioequivalence studies
generally do not reflect the target patient population:
such studies are conducted in healthy subjects aged
18–55 years; patient-related variables and age- and
disease-related (e.g. renal insufficiency) factors are not
considered. In addition, as only single-dose studies are
generally required, the cumulative effects of dosing are
not assessed. Lack of bioequivalence is a particularly
important issue for drugs with a narrow therapeutic
index, such as antiarrhythmics [86].
Many physicians may be unaware of the variation in
bioavailability permitted by regulatory bodies. A survey
conducted in the USA found that only 17% of physicians
correctly identified the FDA’s standards for drugbioequiva-
lence [87]. Based on these findings, Kirking and colleagues
concluded that ‘. . . many physicians are making decisions
regarding generic products on the basis of inaccurate per-
ceptions and beliefs that assume more rigid standards for
bioequivalence than [the] FDA generally requires’ [88].
Formulation differences also occur between the origi-
nal branded drug and the generic version. The authorities
do not require the ‘inactive’ ingredients in a generic formu-
lation to be identical to those in the branded original.
Impurities or small changes in the formulation or excipi-
ents can alter medication properties and introduce unex-
pected effects that affect drug efficacy and safety (e.g. in
duration of action, interactions with other drugs and
patients’ reaction to the drugs) [89]. Formulation differ-
ences have been noted in generic versions of antihyper-
tensives [90–92]. For example, a study of enalapril
formulations found considerable variation in the stability
of different preparations, leading to substantial differences
in drug concentration and drug-release profiles between
the reference and generic formulations [90].Packaging too
can influence a drug formulation’s stability: e.g. losartan/
hydrochlorothiazide tablets have been shown to be sensi-
tive to moisture and adequate packaging must be used to
counter this [93]. Excessive levels of impurities have been
found in generic formulations of a range of different drugs
[91, 94–96].
A study of generic switching, covering 15 different
drugs in Sweden, reported that increasing generic market
share was associated with an increase in the number of
adverse effects reported, suggesting that closer examina-
tion of the consequences of generic substitution is
required [97]. Patients and physicians frequently express
concern about generic formulations and, in some cases at
least, it seems that these concerns are not unfounded.The
FDA recently banned Ranbaxy Laboratories, a pharmaceu-
tical company specializing in generics, from importing 30
generic versions of drugs from India into the USA on the
basis of poor quality [98].
A. Johnston et al.
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The effect of switching on patient
behaviour
As discussed above,patients’ adherence to their antihyper-
tensive treatment regimen is essential for optimal clinical
outcomes. There are many factors associated with switch-
ing that might reduce a patient’s compliance and these
should be taken into account when considering imple-
menting a switch for nonmedical reasons. Even the effect
of changing product packaging and tablet appearance
should be considered as this can cause confusion, particu-
larly in the elderly [99].
Patients are particularly wary of generics, often consid-
ering them to be inferior to the branded versions [100].
This attitude is influenced by the patient’s perception of
the severity of the condition to be treated. A US survey of
consumers’ opinions found that using generics to treat
conditions such as hypertension or ‘heart problems’ was
considered to be riskier than using them to treat pain or a
cough [101]. This and other studies found that many
patients would refuse to switch to generics, regardless of
personal cost savings [101, 102].
A survey conducted in the USA for the National Con-
sumers League revealed that consumers had significant
concerns about therapeutic substitution [103]. Notably,
70% of prescription users stated that theywould be very or
extremely concerned if their prescription was changed
without their doctor’s knowledge or consent and 22% said
that this concern would persist even if their doctor con-
sented to the switch. In patients who experienced thera-
peutic switching, 40% said that the new drug was not as
effective,30% said they experiencedmore side effects, and
47% were dissatisfied with the process. As with generic
switching, patients’ opinions of therapeutic substitution
were influenced by the severity of the condition. For a
chronic conditionwith significant potential health implica-
tions, less than 23% of patients said that they would be
likely to consider a therapeutic substitution.
It has been suggested that concerns about switching
may cause a nocebo effect [100, 104], i.e. patients’ nega-
tive expectations lead to negative outcomes. Many inves-
tigators also report that therapeutic substitution results in
increased reporting of adverse events or negative experi-
ences [19, 102, 105]. In a UK study of primary care patients’
responses to the application of a generic formulary to
their repeat prescriptions, 46% stated that they were dis-
satisfied with the change in prescribing [105]. Within
4 months of the formulary being implemented, 20% of
patients had switched back to their original drug. A key
cause of dissatisfaction seemed to be that patients felt
impotent if they perceived that a change had been forced
on them.
It has been reported that generic substitution per se
does not adversely affect patient adherence [106].
However, a survey of enrollees in managed care organiza-
tions in the USA found that respondents generally agreed
that generic substitution affected their adherence to their
medications [107]. Several investigators have demon-
strated that patients’ adherence to and persistence with
treatment are reduced following switching of antihyper-
tensive drugs [108–111]. For example, in a study of antihy-
pertensive therapy, ‘therapeutic turbulence’ (a switch to
one or more drugs, addition of a new drug, or dropping of
one or more drugs) reduced patients’ persistence [108].
Patients with one change within 6 months of the index
prescription for an antihypertensive drugwere found to be
at greater risk of not persisting than patients without any
drug changes (risk ratio [RR] 1.07, 95% CI 0.94, 1.22).
Patients experiencing two or more changes in the first
6 months were at even greater risk of not persisting (RR
1.25, 95% CI 1.12, 1.37).This difference was statistically sig-
nificant (P < 0.05) and remained so for the first 3 years of
observation.
Similar findings have also been reported regarding
treatment with statins. Patients who switched statins were
significantly less compliant and significantly more likely to
discontinue than those not switching [71, 112].
It is clear that improved communication with the
patient is essential to increase the likelihood of success-
fully switching drugs [102, 113].
Impact on resource use and costs
Medication switching is a cost-containment strategy only if
the potential savings from switching outweigh the costs of
healthcare resources required for the switch.Undoubtedly,
drug acquisition costs are likely to be lowered by imple-
menting switching, but these costs represent only a small
part of the total treatment cost. In the USA, ‘medical
durables’, including prescribed medications, were esti-
mated to represent 11% of the total direct and indirect
costs of cardiovascular disease,and 35% of the total cost of
hypertension in 2009 [114]. In the European Union, medi-
cations were estimated to account for just 16.8% of the
costs of cardiovascular disease in 2003 [115].
Drug acquisition costs are not the only type of cost
affected when drug switching is implemented. As dis-
cussed above, switching can result in poorer adherence
and persistence, increased adverse-event reporting and
reduced effectiveness. A less expensive antihypertensive
agent that causes health problems that need to be
treated, e.g. diabetes caused by b-adrenoceptor blockers,
could increase costs [116]. Conversely, a more expensive
choice of antihypertensive drug that relieves comorbid
clinical problems, e.g. an ARB could delay the progression
to end-stage renal disease in patients with diabetic neph-
ropathy, may help reduce costs overall [117]. Costs
incurred either in the process of switching or as a conse-
quence of switching are thus likely to include those for
administration, additional clinic visits, extra laboratory
tests and possibly hospitalization due to the patient’s
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condition not being adequately controlled by the substi-
tuted drug (e.g. for cardiovascular events associated with
suboptimal blood pressure control [17]). As economic
modelling should consider all possible incurred costs and
should ideally be conducted from the societal perspective
[118], indirect costs should also be considered, including
those associated with lost productivity [119] and informal
care [115].
Potential additional resource use associated with
switching antihypertensives has been investigated by
several investigators [109, 120–130] and switching was
found to incur direct costs. For example, a retrospective
analysis of patients who received ARBs found that those
who switched between ARBs incurred significantly higher
annual all-cause medical costs than those who did not
switch ($6286 vs. $5701, respectively, P < 0.001) [109].
Table 2 illustrates the types of resource identified as being
used in the process of switching antihypertensives (i.e. for
performing the switch) or soon after, and those used in the
longer term (months or years) after such a switch, poten-
tially due to poor blood pressure control. For example,
Lindgren-Furmaga and colleagues investigated the short-
term costs associated with switching from enalapril to lisi-
nopril [122]. At least one follow-up visit was required, with
24% of patients requiring a second visit. Laboratory tests,
drug wastage, pharmacists’ time and telephone contact
with patients were also identified as sources of additional
cost. In total, the direct short-term cost associated with
switching was $66.33 per patient. Based on this cost-
analysis,and not taking into account any longer-term costs
Table 2
Examples of short- and long-term resource use and costs identified as being associated with switching antihypertensives, in addition to drug
acquisition costs
Resource type Resource use or average direct costa (time period after switch) Year of pricingb Reference
Short-term resource use associated with switch implementation
Clinic visit 1.24 ¥ US$52.33c (1989) [122]
1 ¥ US$28.00 (1989/1990) [123]
2 ¥ €7.05 (US$8.64)d 2004 [129]
£3.70e (US$6.73)d 2005 [130]
Laboratory tests US$4.55 (1989) [122]
US$0.00 (1989/1990) [123]
€39.12 (US$47.92)d 2004 [129]
Pharmacy
Prescription filling time US$0.23 (1989) [122]
Setting up programme US$1020 (fixed) (1989/1990) [123]
Adverse reactions
Telephone contact US$0.17f (1989) [122]
Discarded medication US$0.95 (1989/1990) [123]
Office visit US$3.21 (1989/1990) [123]
Drug wastage US$9.05 (1989) [122]
Explaining switch to patients US$1.40f (1989/1990) [123]
£0.32g (US$0.39)d (2005) [130]
Indirect costs NA
Long-term resource use arising from switching antihypertensives
Clinic visits £5 (US$7.50)d increase in cost vs. nonswitchers (1 year) (1992–1994) [121]
US$115 ($28 per visit)h (1 year) 2000 [120]
11% increase in visits, CA$13 (US$9.49)d increase in cost vs. nonswitchersi (2 months) (1996/1997) [127]
18% increase in visits, CA$13 (US$9.49)d increase in cost vs. nonswitchersi (2 months) (1996/1997) [128]
66–78% increase in visits, US$37 increase in cost vs. nonswitchers (1 year) 2002 [124]
Laboratory/diagnostic tests US$31h (1 year) 2000 [120]
Outpatient visits 35–41% increase in outpatient visits, US$20 increase in cost vs. nonswitchers (1 year) 2002 [124]
US$177 increase in cost vs. pre-switch (6 months) (2000–2002) [125]
Hospitalization £24 (US$36)d increase in cost vs. nonswitchers (1 year) (1992–1994) [121]
No significant excess in admissions vs. nonswitchers (2 months) (1996/1997) [127]
No significant excess in admissions vs. nonswitchers (2 months) (1996/1997) [128]
37–42% increase in inpatient visits, US$162–185 increase in cost vs. nonswitchers (1 year) 2002 [124]
Emergency room visits US$4h (1 year) 2000 [120]
Long-term care No significant excess in admissions vs. nonswitchers (2 months) (1996/1997) [127]
No significant excess in admissions vs. nonswitchers (2 months) (1996/1997) [128]
Medication Increase of US$28 compared with pre-switch, co-payment increased by US$9 (6 months) (2000–2002) [125]
Indirect costs NA
aCost given per patient unless otherwise stated. bWhere year of pricing is not stated, the years covered by the study are given in brackets. cThe authors estimated that 24% of patients
would require a second visit to adjust dosage. dApproximate value, based on historical exchange rate. eIncludes time spent by general practitioner (£2.77) and time for repeat blood
pressure measurements (£0.93). fPharmacist’s time. gPostage costs. hNo control (nonswitchers) group. iCosts not specified but ‘reflected increased number of visits to physicians’.
NA, no information available.
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thatmight be incurred,the authors calculated that it would
take up to 17 months for the reduced drug acquisition
costs to mitigate the costs associated with the switch. In
the longer term, additional healthcare resources could be
required, such as hospitalization and emergency room
visits, because of poorly controlled hypertension. Muraw-
ski & Abdelgawad looked at costs incurred in the year fol-
lowing switches due to implementation of a preferred
drug list for ARBs, ACEIs and calcium-channel blockers
(CCBs) [124].The authors noted substantial increases in the
numbers of clinic, hospital inpatient and outpatient visits
in the population that switched compared with a control
population (Table 2). Based on these events alone, and not
including the costs of implementing the programme, the
authors calculated that an additional annual cost would be
incurred of $219–242 per patient who switched antihyper-
tensive drug as part of the preferred drug list programme
(2002 costs). Similarly, although some studies of statin
switching have found no additional costs incurred through
switching [131], others have noted increased resource use
and costs incurred through additional clinic visits, labora-
tory tests, and laboratory technician and pharmacist time
[132–135]. It is important to note that such costs have not
always been included in economic evaluations of switch-
ing programmes.
Of the resource types investigated in studies of antihy-
pertensive switching, additional clinic visits are a key cost
driver. These are likely to be required for a variety of
reasons including increased communication with patients
to explain and reassure them about the switch.A UK study
of primary care patients’ responses to switching to a
generic formulary found that for every 100 intended pre-
scription changes, 16 additional consultations were gener-
ated [105]. Therapeutic switching is also likely to involve
dose titration of the new drug. For example, a study of
switching from CCBs to amlodipine/benazepril noted that
44% of patients required one dose titration and 16%
required two [120]. Additional physician or hospital visits
may be required to address treatment failure or new
adverse events after the switch [124]. Finally, patients
sometimes switch back to their original drug, generating
further rounds of clinic visits [19, 105, 130, 136].
The potential impact of poor compliance with therapy
is not often taken into account in cost-effectiveness analy-
ses [137]. However, several studies have highlighted the
additional resource use and costs incurred by poor adher-
ence to antihypertensives [64, 136–144]. Greater compli-
ance with antihypertensive therapy has been shown to be
associated with lower costs for physician, hospital and
laboratory services [140, 143]. In particular, several investi-
gators have noted that the risk of hospitalization, and
hence hospitalization costs, increases with poorer adher-
ence to and persistence with antihypertensive therapy
[64, 65, 139]. Little is known about the effect on indirect
costs of antihypertensive treatment adherence and persis-
tence. However, Rizzo and colleagues estimated that a
personwith uncontrolled hypertension loses 5.5work days
per year and that 3.5 of the disability days could be
avoided if treatment adherence was optimized [142]. It is
clear that the potential impact of reduced adherence and
persistence on the cost-effectiveness of switching should
not be ignored.
Researchers have warned that although formulary
access restrictions are designed to reduce costs, ‘. . . if they
cause a drop in patient persistence, or a flurry of activity
(switching) with each new list that is adopted, there could
be negative consequences for both patients and the Med-
icaid budget’ [110].This appears to be borne out by recent
studies of real-world switching policies that have high-
lighted the potential ‘unintended consequences’of switch-
ing and the need to consider more than just drug
acquisition costs. A US study of private health insurance
found that step-therapy programmes involving ACEIs and
ARBs incurred net costs compared with controls (no step-
therapy programme) [145]. The step-therapy programme
resulted in medication cost savings, supporting the results
of an earlier study that looked only at medication costs in
a different antihypertensive step-therapy programme
[146]. However, antihypertensive use declined and inpa-
tient and emergency room admissions increased in the
step-therapy group compared with controls. Gradually the
costs incurred increased, such that by 2 years after initia-
tion of step therapy, the average quarterly cost per patient
was $99 higher in the step-therapy group than in the
control group [145]. Similar findings have been reported in
other therapeutic areas. A review of a therapeutic substi-
tution policy for proton pump inhibitors noted that man-
dated therapeutic substitution may result in higher levels
of healthcare resource use.The policy implementation was
estimated to have a total net healthcare cost of up to
CA$43.5 million [147].
In addition to the economic costs of switching, the
human costs should also be considered:what is the impact
of switching antihypertensives on patients’ quality of life?
At present there is little information on this aspect of
switching.
To our knowledge, there is no adequately powered, ran-
domized clinical trial demonstrating the cost-effectiveness
of a medication switching strategy in hypertension. Any
economic model of cost-effectiveness needs to consider a
wide range of healthcare resource use and it should also
take into account any detriment to patients’ quality of life
caused by switching.
Conclusions
Although evidence-basedmedicine should be the primary
consideration when selecting optimal patient treatment,
medications are an easily identifiable target when health-
care costs are under review.Drug switchingwith the aim of
reducing healthcare costs in hypertension management is
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relatively common. However, before implementing a drug
switch the potential impact on disease control and the true
economic cost must be carefully considered.
The principles of evidence-based medicine should still
apply when considering switching drugs. However, a com-
plete and thorough analysis of all the clinical implications
of switching has yet to be performed. Medication switch-
ing has not been the subject of many clinical trials and
much of the data pertain to surrogate markers rather than
clinical outcomes. Thus, there is currently little available
clinical evidence on which the physician or pharmacist can
base his/her decision to switch medications. Differences
between medications may be subtle but have long-term
consequences that are as yet unknown. For example, anti-
hypertensive agents have different pharmacodynamic and
pharmacokinetic properties and potentially different treat-
ment effectiveness, despite belonging to the same drug
class.Any switching of antihypertensive therapies can only
be implemented after careful consideration of the suitabil-
ity of a specific drug for a particular individual, taking into
account theirmedical history including comorbidities,con-
current medications and previous therapies.The impact of
possible interruptions to optimal drug therapy because of
the need for titration should also be borne in mind. The
impact of switching must also be considered from the
patient’s perspective – will switching compromise treat-
ment effectiveness because the patient is dissatisfied with
their new treatment? Similarly, the costs incurred through
switching need to be carefully analysed. Drug acquisition
costs constitute only a small part of the total treatment
cost and switching is likely to incur costs through other
aspects of healthcare provision, such as additional clinic
visits and laboratory tests, as well as costs arising from any
adverse effects of switching, including poorly controlled
hypertension.
In an ideal world, the question of whether the potential
costs of drug substitution in hypertension are outweighed
by its benefits would be investigated by randomized con-
trolled trials before such policies are recommended for
wide application in clinical practice. However, real-world
observational studies and patient databases can also
provide useful information on the possible impact of
switching medications [148]. Although the cost of treat-
ment should always be considered, such considerations
should not predominate over effectiveness and tolerability
issues in any individual patient.
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